Table 4. Five-year absolute survival under different assumptions regarding survival status among incident cancer cases registered in 1990–1999 and followed through 2001, PBCR, Chennai, India.
| Tumour site/type | 5-year absolute survival (%) |
||||
|---|---|---|---|---|---|
| Passive follow-up |
Active follow-up |
||||
| Case 1a | Case 2b | Case 3c | Case 4d | ||
| Lip | 79.5 | 44.6 | 40.7 | 39.5 | |
| Tongue | 62.1 | 29.2 | 19.4 | 15.4 | |
| Oral cavity | 68.5 | 37.1 | 30.5 | 26.4 | |
| Tonsil | 58.5 | 17.2 | 13.7 | 10.8 | |
| Hypopharynx | 59.2 | 20.0 | 12.5 | 9.6 | |
| Oesophagus | 48.9 | 12.9 | 6.9 | 5.0 | |
| Stomach | 47.9 | 15.0 | 8.6 | 5.6 | |
| Pancreas | 41.8 | 10.9 | 7.9 | 6.5 | |
| Larynx | 59.0 | 35.1 | 30.7 | 28.4 | |
| Lung | 40.8 | 13.2 | 6.5 | 4.2 | |
| Breast | 71.6 | 51.5 | 43.7 | 39.6 | |
| Cervix | 75.5 | 59.0 | 54.0 | 49.4 | |
| Ovary | 60.1 | 39.5 | 27.4 | 21.1 | |
| Urinary bladder | 61.3 | 31.0 | 23.2 | 20.0 | |
| Hodgkin lymphoma | 69.1 | 42.6 | 39.4 | 35.9 | |
| Non-Hodgkin lymphoma | 55.6 | 29.7 | 21.6 | 16.8 | |
| Lymphoid leukaemia | 54.3 | 26.5 | 23.8 | 15.5 | |
| Myeloid leukaemia | 40.4 | 21.5 | 14.7 | 10.9 | |
| Leukaemia, type unspecified | 32.9 | 17.8 | 10.9 | 6.2 | |
PBCR, population-based cancer registry. a Case 1: Passive follow-up only, with cancer cases not matched with those in the official mortality database presumed to be alive on the closing date. b Case 2: Passive and active follow-up, with cases lost to follow-up presumed to be alive on the closing date. c Case 3: Passive and active follow-up, with cases lost to follow-up censored on the last date their survival status was known. d Case 4: Passive and active follow-up, with cases lost to follow-up excluded from survival analysis.